

Summary of Studies Supporting USDA Product Licensure

Establishment Name	Huvepharma, Inc.
USDA Vet Biologics Establishment Number	605
Product Code	1U11.R0
True Name	Clostridium Perfringens Type A Vaccine, Live Salmonella Vector
Tradename(s) / Distributor or Subsidiary (if different from manufacturer)	Avert NE - No distributor specified
Date of Compilation Summary	November 03, 2020

Disclaimer: Do not use the following studies to compare one product to another. Slight differences in study design and execution can render the comparisons meaningless.

Study Type	Efficacy							
Pertaining to	Clostridium	perfringens	type A					
Study Purpose	Efficacy against necrotic enteritis due to <i>Clostridium perfringens</i>							
	Type A							
Product	Initial dose a	administered	l by coarse	e spray at day	-of-age (Study	Day 1)		
Administration	and second of	lose admini	stered in d	rinking water	at 11 days of	age		
	(Study Day	11)						
Study Animals	Group 1: No	n-vaccinate	d, non-cha	llenged sentin	nel control			
	Group 2: No	n-vaccinate	d, <i>Eimeria</i>	<i>maxima</i> trea	ted control			
	Group 3: Pla	cebo vaccir	nated, Eim	eria treated ar	nd Clostridium	1		
	challenge							
	Group 4: Pro	oduct vaccir	nated (Vaco	cine), Eimeria	treated and			
	Clostridium	challenge						
Challenge	Chickens we	ere treated w	vith Eimeri	<i>a maxima</i> oo	cysts on Study	v Day 14		
Description	and challeng	ged with Clo	ostridium p	erfringens on	Study Days 1	9, 20 and		
	21							
Interval observed	Observed tw	rice daily for	r 10 days a	fter challenge	e. Birds that su	uccumbed		
after challenge	during the ol	oservation p	period were	e evaluated fo	r intestinal les	ions.		
-	Remaining birds were humanely euthanized on Study Day 28.							
Results	N N	fortality afte	er Challeng	ge due to Nec	rotic Enteritis			
				1	1			
	Treatment	Number	Vaccine	Eimeria	С.	Results		
	Group	Chickens		inoculation	perfringens			
					challenge			
	1	16	None	-	-	0/14		
	2	80	None	+	-	0/75		
	3	192	Placebo	+	+	58/180*		
	4	192	Vaccine	+	+	16/173*		
	* Death due	to necrotic	enteritis (c	onfirmed by 1	necropsy) per	total birds		
	challenged							
USDA Approval	June 17, 201	9						
Date								

Treatment	Chickens	Mortality Due to Necrotic Enteritis by Day After Challenge								nge	
Group	Challenged	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7	Day 8	Day 9	Day 10
3	180	0	0	24	16	14	4	0	0	0	0
4	173	0	0	10	2	3	1	0	0	0	0

Study Type	Efficacy								
Pertaining to	Clostridium	perfringens	type A						
Study Purpose	Efficacy against necrotic enteritis due to Clostridium perfringens								
	Туре А								
Product	One dose administered by course spray at day of age (Study Day 1)								
Administration			-						
Study Animals	Group 1: No	n-vaccinate	d, non-cha	llenged sentin	nel control				
-	Group 2: No	n-vaccinate	d, <i>Eimeria</i>	<i>maxima</i> trea	ted control				
	Group 3: Pla	cebo vaccir	nated, Eim	eria treated ar	nd Clostridium	ı			
	challenge								
	Group 4: Pro	oduct vaccir	nated (Vaco	cine), Eimeria	a treated and				
	Clostridium	challenge							
Challenge	Chickens we	ere treated w	vith Eimeri	<i>a maxima</i> oo	cysts on Study	v Day 14			
Description	and challeng	ged with Clo	ostridium p	erfringens on	Study Day 19)			
Interval observed	Observed tw	rice daily fo	r 10 days a	fter challenge	e. Birds that su	uccumbed			
after challenge	during the ol	oservation p	eriod were	e evaluated fo	r intestinal les	ions.			
	Remaining birds were humanely euthanized on Study Day 28.								
Results	Mortality after Challenge due to Necrotic Enteritis								
	Treatment	Number	Vaccine	Eimeria	С.	Results			
	Group	Chickens		inoculation	perfringens				
					challenge				
	1	16	None	-	-	0/15			
	2	80	None	+	-	0/79			
	3	192	Placebo	+	+	68/191*			
	4	192	Vaccine	+	+	25/191*			
	* Death due	to necrotic	enteritis (c	onfirmed by 1	necropsy) per	total birds			
	challenged								
USDA Approval	April 30, 202	20							
Date	1								

Treatment	Chickens		Ν	Iortality I	Due to Ne	ecrotic Er	nteritis by	v Day Aft	er Challe	nge	
Group	Challenged	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7	Day 8	Day 9	Day 10
3	191	0	35	32	1	0	0	0	0	0	0
4	191	0	12	13	0	0	0	0	0	0	0

Study Type	Safety								
Pertaining to	All fraction	All fractions							
Study Purpose	To demonstrate safety under field conditions								
Product Administration	Two doses	: Administere	d by coarse spra	y at day of a	ige and at 14				
	days of age	e via drinking	water		-				
Study Animals	Commerci	al broiler chic	kens day of age						
Challenge Description	N/A								
Interval observed after	Chickens v	vere observed	daily for 21 day	ys after vacc	ination.				
challenge									
Results	Total Mort	tality for Vacc	inates and Cont	rols*					
	Site	Treatment	Number of	Mortality	Percent				
			Chickens		Mortality				
				1070	0.10				
	1	Vaccinates	63,900	1378	2.16				
		Controls	64,160	2454	3.82				
	2	Vaccinates	43,600	641	1.47				
		Controls	44,220	1031	2.33				
	*Mortality	of controls at	each site is the	average mor	tality of five				
	previous flocks at the same site.								
	1								
	No adverse reactions attributable to the vaccine were observed.								
USDA Approval Date	09/22/2020)							

Study Type	Safety								
Pertaining to	All fractions								
Study Purpose	To demonstrate safety under field conditions								
Product Administration	One dose:	Administrated	l by coarse spra	y at day of a	ge				
Study Animals	Commerci	al broiler chic	kens day of age						
Challenge Description	N/A								
Interval observed after	Chickens v	vere observed	daily for 21 day	ys after vacc	ination.				
challenge									
Results	Total Mort	ality for Vacc	inates and Cont	rols*					
	Site	Treatment	Number of	Mortality	Percent				
			Chickens		Mortality				
	1 Vaccinates 76,768 1261 1.6								
		Controls	78,346	1367	1.75				
	2	Vaccinates	60,000	1994	3.32				
		Controls	60,680	1667	2.75				
	*Mortality of controls at each site is the average mortality of five previous flocks at the same site.No adverse reactions attributable to the vaccine were observed.								
USDA Approval Date	09/22/2020)							